On December 19, 2022 iPSirius reported the company got $2M Award from European Innovation Council to Develop a Novel Stem Cell Vaccine to Help Cancer Patients Worldwide (Press release, iPSirius, DEC 16, 2022, https://bioinformant.com/ipsirius/ [SID1234640999]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Pivotal to the company bringing these new cancer vaccines to the clinic is the innovative technology that won a very competitive Pathfinder Award from the European Innovation Council. This secured $2M to translate the technology to the clinic. The European Innovation Council gives out the EIC Pathfinder award to "support research teams to develop emerging breakthrough technologies".

"We are very grateful to European Innovation Council for this necessary financial support that will accelerate access of our stem cell vaccine pipeline to the clinic. Our team at iPSirius is eager to develop off-the-shelf, cell-based vaccines that can improve the quality of life for patients with aggressive cancers worldwide. We hope that these new cancer vaccines will be transformative to the field of cancer therapy," said co-Founder and Chief Medical Officer, Prof Ali Turhan.

iPSirius is addressing key challenges in treating non-immunogenic solid tumors, based on the immunogenic properties of stem cells.

More details can be found at the company website, www.iPSirius.com.